Category stocks

Repligen Expands Cell Therapy Business

Repligen buys BioLife for $1.5 billion Repligen Corp is acquiring BioLife Solutions in a deal valued at $1.5 billion. The acquisition aims to expand Repligen's presence in the cell therapy market. The purchase price includes $11.25 in cash and 0.1442 shares of Re